期刊文献+

缬沙坦联合吲哒帕胺治疗高血压的临床研究

The clinical study on valsartan combined with indapamide in the treatment of hypertension
下载PDF
导出
摘要 目的:探讨缬沙坦联合吲哒帕胺治疗高血压的临床效果。方法:选取280例高血压患者资料进行回顾性分析,随机分为观察组(100例)和对照组(对照A组90例、B组90例)。所有患者均停用其他降压药物2周左右。对照A组给予缬沙坦,对照B组给予吲哒帕胺;观察组给予缬沙坦联合吲达帕胺,3组均连续治疗8周。结果:治疗前,3组患者血压比较无显著性差异;用药治疗后观察组血压降低幅度明显高于对照组,总有效率比较有显著性差异(x2=6.472,P<0.05)。结论:缬沙坦联合吲哒帕胺治疗高血压病具有起效快、疗效和持续时间长及不良反应少的特点,是治疗高血压的理想选择,值得临床推广和应用。 Objective: To explore the clinical effect of valsartan combined with indapamide in the treatment of hypertension. Methods: In our hospital in 2012 August - 2015 August treatment of 280 cases of hypertensive patients, all patients had drug withdrawal for 2 weeks. Were randomly divided into observation group 100 cases and control group 1, control group 2 of the 90 cases, control group 1 given valsartan, control group 2 given indapamide, the observation group were given valsartan combined with indapamide, were treated for 8 weeks. Results: three groups of patients before treatment, the blood pressure were not significantly different, after the treatment, the observation group decreased blood pressure was significantly higher than that in control group, the total effi^ency had significant difference (x2=6.472, P〈0.05) Conclusion: Valsartan combined with indapamide in the treatment of hypertension has fast acting, high curative effect, long duration, few adverse reactions, is the ideal choice for the treatment of hypertension, is worth the clinical promotion and application.
出处 《中国医学装备》 2014年第10期120-123,共4页 China Medical Equipment
基金 河北省科技攻关计划(060206)"缬沙坦联合吲哒帕胺治疗高血压病的临床药物研究"
关键词 缬沙坦 吲哒帕胺 高血压 不良反应 Valsartan Indapamide I4ypertension Adverse reaction
  • 相关文献

参考文献9

  • 1张维忠.2004年高血压研究的循证医学新进展[J].中国循证医学杂志,2005,5(3):185-187. 被引量:21
  • 2姜国田,钱学礼.缬沙坦与吲哒帕胺联合治疗高血压40例临床观察[J].重庆医学,2009,38(23). 被引量:5
  • 3Zanchetti A.Twenty-four-hour ambulatory blood pressure evaluation of antihypertensive agents[J]. Hypertens, 1997, 15 (7Supp 1 ): $21 -$25.
  • 4蒲章深.缬沙坦与缬沙坦加吲哒帕胺的降压效果比较[J].实用医药杂志,2008,25(5):549-549. 被引量:4
  • 5Hayden MR,Tyagi SO.Uric acid.a new look at an old riskmarker for cardiovascular disease, metabolic syndrom, and typ2diabetes, the urate redix shutle[J]. Nutr Metab, 2004, 1 (1) : 10.
  • 6Markham A,Goa KL.Valsaratan.A review of its pharmacology andtherapeatic use in essential hypertension[J]. Drugs, 1997,54(2).. 299-311.
  • 7Muller P,Cohen T,de Gasparo M,et al.Angio- tensin11 receptorblockade with single dose of vaslsartan in healthy normotensivesubjects[J].Eur J Clin pharmacol, 1994,47(3) .. 231-245.
  • 8Ikeda N,Nishimura S,Kyo S,et al.Valsartan cardio-renal protection inpatients undergoing coronary angiography complicated with chronicrenal insufficiency(VAL- C ARP)trial. rationale and design[J]. Circ J, 2006,70(5).. 548-552.
  • 9陶军.高血压与血管内皮功能[J].中国实用内科杂志,2009,29(9):783-786. 被引量:48

二级参考文献4

  • 1Markham A,Goa KL. Valsaratan A review of its pharmacology and therapeatic use in essential hypertension[J]. Drugs, 1997,54 : 299.
  • 2Hayden MR,Tyagi SC.Uric acid:a new look at an old risk marker for cardiovascular disease,metabolic syndrom,and typ2 djabetes:the urate redix shutle.Nutr Metab,2004,1:101.
  • 3Nishikebe M,Ikemoto F.Pharmacological properties and its significance in clinical practice.Nippo-Rinsho,1999.1124-1129.
  • 4Juan GP,Felicitas M,Anionio B,et al.Effect of eprosartan and losartan of uric acid.J Hypertension,1999,17(7):1033,

共引文献68

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部